October 2026 — Amiens, France

Glyx Therapeutics has joined the Brain&Mind community, a strategic step in the development of our molecules targeting tauopathies.

What this brings to Glyx

• Access to a network of experts specialized in neuroscience and neurodegenerative diseases
• Synergies with other players engaged in research on cognitive disorders
• Collaboration opportunities to accelerate the preclinical and clinical validation of our therapeutic approaches

This step follows our recent results, including the in vitro validation of the proof of concept and of the mechanism of action on the anti-hyperphosphorylation and anti-aggregation of the Tau protein. We are convinced that this alliance will strengthen our ability to turn our research into concrete solutions for patients with tauopathies.

Learn more about our pipeline, our research on tauopathies and Alzheimer’s disease, or about Glyx Therapeutics.